Therefore, targeting glutaminolysis using glutaminase inhibitors presents a promising therapeutic approach for aggressive subtypes of lung cancer with mutations in KEAP1/NRF2 (Romero et al
These programs encompassed 79 unique pharmacological agents, 61 of which have anti-cancer indications (Supplementary Data 5)
Check the PAN Foundation website for current status
Healthcare professionals should be informed if a patient discloses use of unlicensed injectables, as this is directly relevant to clinical assessment and ongoing care
When combined with clinical assessment and injection technique optimization, genetic context may help anticipate tolerability and optimize your treatment plan
PubMed Central, Garner, Tyler Bruce, et al